PMID: 6133444May 1, 1983Paper

Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction

The American Journal of Cardiology
M F RousseauM F Vincent


Corwin is a new selective beta 1 partial agonist, able to stabilize the beta 1 adrenoceptors at approximately 43% of their maximal activity. The aim of the study was to determine the effects of this agent in patients with coronary artery disease (CAD) and previous myocardial infarction (MI). In a first group of 14 patients, corwin increased significantly the peak (+)dP/dt (+35%; p less than 0.005), the global ejection fraction, and the ejection fraction of abnormally contracting segments (from 20 +/- 18 to 26 +/- 19%; p less than 0.02). Corwin also induced significant decreases in mean systolic (-8%; p less than 0.05) and mean diastolic (-38%; p less than 0.001) wall stress and accelerated the relaxation rate. In a second group of 11 patients, a metabolic study indicated that neither myocardial oxygen consumption (15 +/- 7 versus 15 +/- 7 ml/min; difference not significant) nor lactate extraction was modified by the drug. In this group, increases in peak (+)dP/dt, acceleration in ventricular relaxation (-8 ms in time constant of isovolumic pressure decrease; p less than 0.01), and decreases in left ventricular end-diastolic pressure also were noted after administration of corwin, both under basal conditions and during a cold pr...Continue Reading


Nov 1, 1982·The American Journal of Cardiology·M F RousseauL A Brasseur

❮ Previous
Next ❯


Sep 1, 1990·Clinical Cardiology·L ThierfelderH J Just
Jan 1, 1986·European Journal of Clinical Pharmacology·R J BowesA Harley
Feb 1, 1993·Cardiovascular Drugs and Therapy·H E BøtkerE V Sørensen
Jun 24, 1986·European Journal of Pharmacology·E Vigholt Sørensen, F Nielsen-Kudsk
Mar 30, 2005·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Bao Ting Zhu
Jun 1, 1984·Journal of the American College of Cardiology·E Braunwald, W S Colucci
Dec 1, 1989·British Journal of Clinical Pharmacology·D P NichollsR G Shanks
Mar 1, 1990·Postgraduate Medical Journal·M J Kendall, R C Horton
Apr 1, 1990·Cardiovascular Drugs and Therapy·M de MarneffeM Englert
Jan 1, 1986·European Journal of Clinical Pharmacology·L BarriosH de Geest
Feb 1, 1984·The American Journal of Cardiology·J M DetryL A Brasseur
May 1, 1989·British Journal of Clinical Pharmacology·D B Barnett
Jan 1, 1989·British Journal of Clinical Pharmacology·H M Snow
Jan 1, 1989·British Journal of Clinical Pharmacology·M F RousseauA A Charlier
Feb 1, 1989·Journal of Clinical Pharmacy and Therapeutics·M K Davies
Oct 25, 2006·Expert Opinion on Pharmacotherapy·Masao Endoh, Masatsugu Hori
Nov 1, 1986·British Journal of Clinical Pharmacology·J W LammersC L van Herwaarden
May 6, 1991·The American Journal of Cardiology·S J VirkM K Davies
Jan 1, 1989·British Journal of Clinical Pharmacology·D G Waller
Oct 1, 1984·British Journal of Clinical Pharmacology·C G Löfdahl, N Svedmyr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.